Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam versus polymyxin B for carbapenem-resistant Enterobacteriaceae infection
ChiCTR2300067946Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2022
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftazidime + avibactam and polymyxin B in Enterobacteriaceae infection (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: 28-day all-cause mortality and clinical cure rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
ceftazidime + avibactampolymyxin B
03
Conditions
Enterobacteriaceae infection
Beyond the preview
Go deeper on ChiCTR2300067946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067946.